Measurement of vitamin D and cathelicidin (LL-37) levels in patients of psoriasis with co-morbidities

Indian Journal of Dermatology, Venereology and Leprology

Volumn 79, Issue 4, 2013, Pages 492-496

  Al Mutairi, Nawaf ^a   El Eassa, Bayoumi ^b   Nair, Vasanthy ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b FARWANIYA HOSPITAL   (Kuwait)

Author keywords

Antimicrobial peptides; Cathelicidin (LL 37); Psoriasis; Serum vitamin D

Indexed keywords

CATHELICIDIN; VITAMIN D;

ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; HUMAN TISSUE; PSORIASIS VULGARIS; VITAMIN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; VITAMIN D; YOUNG ADULT;

EID: 84880150168     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.113077     Document Type: Article

References (33)

1. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001;15: 16-7.
2. Mrowietz U, Reich K. Psoriasis-New insights into pathogenesis and treatment. Dtsch Arztebl Int 2009;106: 11-9.
3. Morizane S, Gallo RL. Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol 2012;39: 225-30.
4. Gladman DD. Biomarkers for comorbidities in psoriasis: A report from the grappa 2011 annual meeting. J Rheumatol 2012;39: 2193-5.
5. Armstrong AW, Schupp C, Bebo B. Psoriasis comorbidities: Results from the National Psoriasis Foundation surveys 2003-2011. Dermatology 2012;225: 121-6.
6. Onumah N, Kircik LH. Psoriasis and its comorbidities. J Drugs Dermatol 2012;11: s5-10.
7. Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with psoriasis: An experience from the Middle East. J Dermatol 2010;37: 146-55.
8. Orgaz-Molina J, Buendía-Eisman A, Arrabal-Polo MA, Ruiz JC, Arias-Santiago S. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: A case-control study. J Am Acad Dermatol 2012;67: 931-8.
9. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005;26: 662-87.
10. National Institute of Health. Third report of the National Cholesterol Education Program Export Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary 2001. NIH pub no. 01-3670. Bethesda, MD: National Institute of Health, National Heart, Lung and Blood Institute. September 2002; pII-27.
11. Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol 2009;129: 1601-3.
12. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP, et al. Vitamin D and cardiovascular outcomes: A systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96: 1931-42.
13. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: Results from a population-based study. Arch Dermatol 2007;143: 1493-9.
14. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008;19: 5-21.
15. Brøndum-Jacobsen P, Benn M, Jensen GB, Nordestgaard BG. 25-hydroxyvitamin d levels and risk of ischemic heart disease, myocardial infarction, and early death: Population-based study and meta-analyses of 18 and 17 studies. Arterioscler Thromb Vasc Biol 2012;32: 2794-802.
16. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72: 690-3.
17. Ogunkolade BW, Boucher BJ, Prahl JM, Bustin SA, Burrin JM, Noonan K, et al. Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes 2002;51: 2294-300.
18. Yin X, Sun Q, Zhang X, Lu Y, Sun C, Cui Y, et al. Serum 25(OH)D is inversely associated with metabolic syndrome risk profile among urban middle-aged Chinese population. Nutr J 2012;11: 68.
19. Dorjgochoo T, OuShu X, Xiang YB, Yang G, Cai Q, Li H, et al. Circulating 25-hydroxyvitamin D levels in relation to blood pressure parameters and hypertension in the Shanghai Women's and Men's Health Studies. Br J Nutr 2012;108: 449-58.
20. Liu JL, Zhang SQ, Zeng HM. ApaI, BsmI, FokI and TaqI polymorphisms in the vitamin D receptor (VDR) gene and the risk of psoriasis: A meta-analysis. J Eur Acad Dermatol Venereol 2012; Apr 28. doi: 10.1111/j.1468-3083.2012.04553.x. [Epub ahead of print].
21. Dombrowski Y, Schauber J. Cathelicidin LL-37: A defense molecule with a potential role in psoriasis pathogenesis. Exp Dermatol 2012;21: 327-30.
22. Frohm M, Agerberth B, Ahangari G, Stâhle-Bäckdahl M, Lidén S, Wigzell H, et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 1997;272: 15258-63.
23. Dombrowski Y, Peric M, Koglin S, Ruzicka T, Schauber J. Control of cutaneous antimicrobial peptides by vitamin D3. Arch Dermatol Res 2010;302: 401-8.
24. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004;173: 2909-12.
25. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 2005;19: 1067-77.
26. Weber G, Heilborn JD, Chamorro Jimenez CI, Hammarsjo A, Törmä H, Stahle M. Vitamin D induces the antimicrobial protein hCAP18 in human skin. J Invest Dermatol 2005;124: 1080-2.
27. Schauber J, Gallo RL. The vitamin D pathway: A new target for control of the skin's immune response? Exp Dermatol 2008;17: 633-9.
28. Schauber J, Oda Y, Büchau AS, Yun QC, Steinmeyer A, Zügel U, et al. Histone acetylation in keratinocytes enables control of the expression of cathelicidin and CD14 by 1,25-dihydroxyvitamin D3. J Invest Dermatol 2008;128: 816-24.
29. Morizane S, Yamasaki K, Kabigting FD, Gallo RL. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid. J Invest Dermatol 2010;130: 1297-306.
30. Segaert S. Vitamin D regulation of cathelicidin in the skin: Toward a renaissance of vitamin D in dermatology? J Invest Dermatol 2008;128: 773-5.
31. Zelezetsky I, Pontillo A, Puzzi L, Antcheva N, Segat L, Pacor S, et al. Evolution of the primate cathelicidin. Correlation between structural variations and antimicrobial activity. J Biol Chem 2006;281: 19861-71.
32. Braff MH, Hawkins MA, Di Nardo A, Lopez-Garcia B, Howell MD, Wong C, et al. Structure-function relationships among human cathelicidin peptides: Dissociation of antimicrobial properties from host immunostimulatory activities. J Immunol 2005;174: 4271-8.
33. Dombrowski Y, Peric M, Koglin S, Kammerbauer C, Göss C, Anz D, et al. Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci Transl Med 2011;3: 82ra38.